89bio to participate in the h.c. wainwright bioconnect 2021 conference

San francisco, jan. 04, 2021 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that rohan palekar, the company's chief executive officer, will provide a corporate update at the virtual h.c. wainwright bioconnect 2021 conference to be held january 11-14, 2021.
ETNB Ratings Summary
ETNB Quant Ranking